All News
Sniffles & Arthritis (3.1.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Are these associations with infection, biomarkers and weather real or imaginary? Linked or luck? Causal or casual? You decide....
Read Article
Many with Psoriatic Arthritis Fail to Achieve Minimal Disease Activity
Despite the availability of numerous advanced therapies for psoriatic arthritis (PsA), there remains a substantial burden and unmet need for improved therapies, according to a newly published Canadian study.
Read Article
Polyarteritis Nodosa: Clinical Features and Outcomes
A multinational study of polyarteritis nodosa (PAN) through the international GLOBAL-PAN network shows PAN to be a complex, multisystem disorder with a high risk of relapse and low risk of death (11% at 10 years).
Read Article
Excess Cardiovascular Risk in Gout
A UK population cohort study has shown that gout carries an increased risk for a wide variety of cardiovascular disorders.
Read Article
EGPA: Benralizumab (BEN) or Mepolizumab (MEP)
A multicenter, double-blind, phase 3, randomized, active-controlled trial has shown that BEN was noninferior to MEP for the induction of remission of patients with relapsing or refractory EGPA.
https://t.co/V0qWQ5nOzc https://t.co/SoOid5HKcV
Dr. John Cush RheumNow ( View Tweet)
Behçet’s Syndrome
A comprehensive overview of Behcet's syndrome appeared in last week's NEJM, reviewing the numerous advances in the immunogenetics, syndrome recognition, and targeted therapeutic approaches.
https://t.co/Yb3R4K9Zwf https://t.co/JAxqZ3FcQz
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA approves 10th adalimumab biosimilar - called Simlandi (adalimumab-ryvk), from Alvotech and Teva. Unique in that it's the 1st high-concentration, citrate-free & interchangeable ADA biosimilar.https://t.co/Kg7Dqr54dg https://t.co/X25SKggJzN
Dr. John Cush RheumNow ( View Tweet)
When Meningitis Strikes Twice
Amanda Moyer, MD, presents her poster at RWCS 2024.
https://t.co/hO8VkcqCkb https://t.co/9tfKI7dEs9
Dr. John Cush RheumNow ( View Tweet)
CD19 CAR T-Cell Therapy in Autoimmune Disease
The NEJM has published the results of CD19 B cell depletion (by CAR-T cell therapy) in autoimmune disease patients, demonstrating it to be feasible, safe, and efficacious.
https://t.co/D53xeBdgsu https://t.co/dkrJ2CiSTl
Dr. John Cush RheumNow ( View Tweet)
Fever of Unknown Origin: Not Always an Infection
Roel Sanchez Baez, MD presents his poster at RWCS 2024.
https://t.co/WiDfcNHuNv https://t.co/gTs78QmE2A
Dr. John Cush RheumNow ( View Tweet)
Excess Cardiovascular Risk in Gout
A UK population cohort study has shown that gout carries an increased risk for a wide variety of cardiovascular disorders.
https://t.co/ThDbAkI0VN https://t.co/uYz9Swu6sR
Dr. John Cush RheumNow ( View Tweet)
Can Biomarkers Improve Cardiovascular Risk Assessments in RA?
The TARGET (Treatments Against RA and Effect on FDG PET/CT) trial showed that different treatment strategies equally benefited arterial inflammation (by FDG-PET) in rheumatoid arthritis.
https://t.co/NTI57kTtAy https://t.co/idf4qTtKcw
Dr. John Cush RheumNow ( View Tweet)
It's a Sore Subject
Cindy Chiu, DO, presents her poster at RWCS 2024.
https://t.co/Bl7mAL4grR https://t.co/9rLglObu4V
Dr. John Cush RheumNow ( View Tweet)
Sinusitis Linked to 40% Heightened Risk of Rheumatic Disease
The common inflammatory condition sinusitis is linked to a 40% heightened risk of a subsequent diagnosis of rheumatic disease, finds research published in the open access journal RMD Open.
https://t.co/WApFsSzn1W https://t.co/jNv6MClCRk
Dr. John Cush RheumNow ( View Tweet)
Join our experts, Drs Liebowitz and Mehta, as they provide insights on the differential diagnosis and management concepts in autoinflammatory diseases.
https://t.co/FJtWtaxXeG https://t.co/olcRoFZrBY
Links:
Dr. John Cush RheumNow ( View Tweet)
Metabolic signature for fibromyalgia? Study of 54 FM & 31 controls w/ Machine learning to identify 13 metabolic markers that predicted FM w/ 79% accuracy; levels of 5-hydroxyindole-3-acetic acid & glutamine correlated w/ fatigue. https://t.co/YAjffGVATG https://t.co/5UWNpDNioT
Dr. John Cush RheumNow ( View Tweet)
As of 11/23, FDA has approved 44 biosimilars to 14 different reference products. FDA systematic review on biosimilars found no differences in the risk of death, serious adverse events, or treatment discontinuations between the switch and no-switch arms.https://t.co/yVScZnP559 https://t.co/feswD1gJz9
Dr. John Cush RheumNow ( View Tweet)
In 2023, the FDA approved 956 generic drugs and issued 1,493 complete response letters; an improvement on 2022’s 914 approvals and 1,775 complete response letters. https://t.co/XnpQLbxJCr https://t.co/zzf63G4s2R
Dr. John Cush RheumNow ( View Tweet)
IBD extraintestinal & joint manifestations - systematic review of 61 studies (13,806 pts) found 8% new joint findings during advanced therapy (no signif difference betw vedolizumab (9%) & ustekinumab (6%). https://t.co/drFAtBG4ZU https://t.co/N8ixHS64HD
Dr. John Cush RheumNow ( View Tweet)
Mastery of knee arthrocentesis for internal medicine resident
Brian D. Jaros, MD, presents his poster at RWCS 2024.
https://t.co/xFoEGnj2QH https://t.co/DpW07jJTLf
Dr. John Cush RheumNow ( View Tweet)